Journal
AMERICAN JOURNAL OF HYPERTENSION
Volume 30, Issue 9, Pages 914-922Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ajh/hpx067
Keywords
blood pressure; Cornell voltage; electrocardiographic left ventricular hypertrophy; hypertension
Categories
Funding
- National Heart, Lung, and Blood Institute (US NIH) [P20RR011104]
- Pfizer, Inc.
Ask authors/readers for more resources
BACKGROUND Electrocardiographic (ECG) left ventricular hypertrophy (LVH) is a strong predictor of cardiovascular (CV) morbidity and mortality. However, the predictive value of ECG LVH in treated hypertensive patients remains unclear. METHODS A total of 33,357 patients (aged >= 55 years) with hypertension and at least 1 other coronary heart disease (CHD) risk factor were randomized to chlorthalidone, amlodipine, or lisinopril. The outcome of the present study was all-cause mortality; and secondary endpoints were CHD, nonfatal myocardial infarction (MI), stroke, angina, heart failure (HF), and peripheral arterial disease. Cornell voltage criteria (S in V-3 + R in aVL > 28 [men] or > 22 mm [women]) defined ECG LVH. RESULTS ECGs were available at baseline in 26,384 patients. Baseline Cornell voltage LVH was present in 1,741 (7%) patients, who were older (67.4 vs. 66.6 years, P < 0.001), more likely to be female (74 vs. 44%, P < 0001) with a higher systolic blood pressure (151 vs. 146 mm Hg, P < 0.001) than patients without ECG LVH. During 5.0 +/- 1.4 years mean follow-up, baseline and in-study ECG LVH was significantly associated with 29 to 98% increased risks of all-cause mortality, MI, CHD, stroke, and HF in multivariable Cox analyses. CONCLUSIONS Baseline Cornell voltage LVH is associated with increased CV morbidity and all-cause mortality in treated hypertensive patients independent of treatment modality and other CV risk factors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available